The effect of subcutaneous semaglutide injection on blood pressure: a systematic review and meta-analysis of randomized controlled trials
Ahmadi N, Zandi R, Norouzi M, et al. (2026). Diabetes Research and Clinical Practice.
Summary
A systematic review and meta-analysis of placebo-controlled randomised trials of subcutaneous semaglutide. The authors searched MEDLINE, Web of Science and Embase through December 2025 and pooled seven trials with about 20,000 people. Semaglutide lowered systolic blood pressure by 3.46 mmHg compared with placebo (95% confidence interval -4.44 to -2.49), which they rate as high-certainty evidence. The diastolic change was small, -0.56 mmHg (95% confidence interval -0.82 to -0.29). The authors note that the diastolic result depended on one large study and was no longer significant when that study was left out. This pools existing trials; it is not a new trial. The authors declare no competing interests.
Peptides in this study
Semaglutide in the United Kingdom · Semaglutide in the United States · Semaglutide in Australia